(19)
(11) EP 2 270 052 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
02.05.2018 Bulletin 2018/18

(45) Mention of the grant of the patent:
28.03.2018 Bulletin 2018/13

(21) Application number: 10181323.6

(22) Date of filing: 25.06.2002
(27) Previously filed application:
 25.06.2002 EP 09156995
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
G01N 33/53(2006.01)
 A61K 39/395(2006.01)
A61P 19/08(2006.01)

(54)

Antibodies to OPGL

Antikörper gegen OPGL

Anticorps anti-OPGL

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

(30) Priority: 26.06.2001 US 301172 P

(43) Date of publication of application:
05.01.2011 Bulletin 2011/01

(62) Application number of the earlier application in accordance with Art. 76 EPC:
09156995.4 / 2087908
02749660.3 / 1409016

(73) Proprietors:
  • Amgen Inc.
    Thousand Oaks, CA 91320 (US)
  • Amgen Fremont Inc.
    Thousand Oaks, CA 91320 (US)

(72) Inventors:
  • Boyle, William
    Malibu, CA 90265 (US)
  • Martin, Francis
    Newbury Park, CA 91320 (US)
  • Corvalan, Jose
    Foster City, CA 94404 (US)
  • Davis, Geoffrey
    Burlingame, CA 94010 (US)

(74) Representative: Dörries, Hans Ulrich 
df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte PartG mbB Theatinerstrasse 16
80333 München
80333 München (DE)


(56) References cited: : 
WO-A-02/053596
 WO-A1-98/46751
   
  • TSUKII K ET AL: "Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 246, no. 2, 19 May 1998 (1998-05-19), pages 337-341, XP002169940, ISSN: 0006-291X
  • NAGAI M KYAKUMOTO S SATO N: "Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 269, 16 March 2000 (2000-03-16), pages 532-536, XP002956545, ISSN: 0006-291X
  • MARTIN WELSCHOF ET AL: "The Antigen Binding Domain of Non-idiotypic Human Anti-F(ab')2 Autoantibodies: Study of their Interaction with lgG Hinge Region Epitopes", HUMAN IMMUNOLOGY, NEW YORK, NY, US, vol. 60, no. 4, 1 April 1999 (1999-04-01), pages 282-290, XP008131561, ISSN: 0198-8859
  • PAVLINKOVA G ET AL: "Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts.", JOURNAL OF NUCLEAR MEDICINE : OFFICIAL PUBLICATION, SOCIETY OF NUCLEAR MEDICINE SEP 1999 LNKD- PUBMED:10492377, vol. 40, no. 9, September 1999 (1999-09), pages 1536-1546, XP002616970, ISSN: 0161-5505
  • FOR THE ATTRACT STUDY GROUP MAINI R ET AL: "Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 354, no. 9194, 4 December 1999 (1999-12-04), pages 1932-1939, XP004827470, ISSN: 0140-6736, DOI: DOI:10.1016/S0140-6736(99)05246-0
  • 3, 24: In: Alberts et al: "Molecular Biology Of The Cell - fourth edition", 2002, Garland Science, New York page 162, 1380, 1381,
  • KATO Y ET AL: "Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas", NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER, NY, US, vol. 37, no. 7, 1 October 2010 (2010-10-01), pages 785-794, XP027325962, ISSN: 0969-8051 [retrieved on 2010-09-23]
  • ABRAHAM R ET AL: "Determination of binding constants of diabodies directed against prostate-specific antigen using electrochemiluminescence-based immunoassays", JOURNAL OF MOLECULAR RECOGNITION, HEYDEN & SON LTD., LONDON, GB, vol. 9, no. 5-6, 1 September 1996 (1996-09-01), pages 456-461, XP002381122, ISSN: 0952-3499, DOI: 10.1002/(SICI)1099-1352(199634/12)9:5/6<45 6::AID-JMR282>3.0.CO;2-8
  • LARVOR M P ET AL: "Measurement of the dissociation rate constant of antigen/antibody complexes in solution by enzyme-linked immunosorbent assay.", JOURNAL OF IMMUNOLOGICAL METHODS 15 APR 1994, vol. 170, no. 2, 15 April 1994 (1994-04-15), pages 167-175, ISSN: 0022-1759
  • ZHUANG G ET AL: "Measurement of association rate constant of antibody-antigen interaction in solution based on enzyme-linked immunosorbent assay.", JOURNAL OF BIOSCIENCE AND BIOENGINEERING 2001, vol. 92, no. 4, 2001, pages 330-336, ISSN: 1389-1723
  • HARDY F ET AL: "Measurement of antibody/antigen association rate constants in solution by a method based on the enzyme-linked immunosorbent assay.", JOURNAL OF IMMUNOLOGICAL METHODS 15 JAN 1997, vol. 200, no. 1-2, 15 January 1997 (1997-01-15), pages 155-159, ISSN: 0022-1759
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).